Table 4.

Summary of AEs and SAEs (Safety Population)

	Lumiracoxib 100 mg o.d. (n = 755)	Lumiracoxib 100 mg b.i.d. (n = 1,519)	Celecoxib 200 mg o.d. (n = 758)
Patients with AEs, n (%)	548 (72.6)	1078 (71.0)	526 (69.4)
Patients with SAEs, n (%)	41 (5.4)	72 (4.7)	48 (6.3)
Fatal, n (%)†	2 (0.3)	7 (0.5)	1 (0.1)
Discontinuations due to AEs, n (%)	98 (13.0)	193 (12.7)	87 (11.5)

o.d. = once daily; b.i.d. = twice daily; AEs = adverse events; SAEs = serious adverse events; ^†all deaths occurring before database lock are included.